Immucillin-H
Structural formula | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||
Non-proprietary name | Forodesin | |||||||||||||||
other names |
Immucillin-H |
|||||||||||||||
Molecular formula | C 11 H 14 N 4 O 4 | |||||||||||||||
External identifiers / databases | ||||||||||||||||
|
||||||||||||||||
Drug information | ||||||||||||||||
Drug class |
Antiviral agent , nucleoside reverse transcriptase inhibitors |
|||||||||||||||
properties | ||||||||||||||||
Molar mass | 266.25 g mol −1 | |||||||||||||||
safety instructions | ||||||||||||||||
|
||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Immucillin-H , Forodesin INN (manufacturer: BioCryst Pharmaceuticals) is a new type of active ingredient for the targeted therapy of malignant haematological diseases, in particular acute T-cell leukemia (T-ALL) . Immucillin-H belongs to the group of PNP inhibitors and is currently being tested for its safety and effectiveness in various clinical studies .
Mechanism of action
Immucillin-H inhibits the function of the enzyme purine nucleoside phosphorylase ( PNP ) and thus leads to a selective reduction in T lymphocytes in the patient's blood.
Indications
Adults
For Immucillin-H, the following indications are currently being investigated in initial clinical studies (phase II) :
- Acute T-cell leukemia (T-ALL )
- Chronic lymphatic leukemia (CLL)
- T-cell (lymphoblastic) lymphoma
literature
- Gandhi V. et al. (2005): A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood 106 (13); 4253-4260; PMID 16131572 ; PDF (free full text access)
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.